Bradley Foster & Sargent Inc. CT Has $44.31 Million Holdings in Boston Scientific Corporation $BSX

Bradley Foster & Sargent Inc. CT decreased its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 18.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 453,864 shares of the medical equipment provider’s stock after selling 100,560 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in Boston Scientific were worth $44,311,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of BSX. Brighton Jones LLC grew its stake in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares in the last quarter. D.A. Davidson & CO. grew its position in Boston Scientific by 9.5% in the 2nd quarter. D.A. Davidson & CO. now owns 12,632 shares of the medical equipment provider’s stock worth $1,357,000 after purchasing an additional 1,096 shares in the last quarter. Leavell Investment Management Inc. increased its stake in Boston Scientific by 6.3% in the 2nd quarter. Leavell Investment Management Inc. now owns 2,190 shares of the medical equipment provider’s stock valued at $235,000 after buying an additional 129 shares during the last quarter. Solstein Capital LLC bought a new position in shares of Boston Scientific during the 2nd quarter worth approximately $39,000. Finally, Ashton Thomas Private Wealth LLC increased its holdings in Boston Scientific by 74.8% in the 2nd quarter. Ashton Thomas Private Wealth LLC now owns 11,607 shares of the medical equipment provider’s stock worth $1,247,000 after acquiring an additional 4,966 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Boston Scientific stock opened at $75.27 on Wednesday. The stock has a market cap of $111.70 billion, a price-to-earnings ratio of 38.80, a PEG ratio of 1.03 and a beta of 0.67. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The business has a 50-day simple moving average of $88.52 and a 200 day simple moving average of $96.13. Boston Scientific Corporation has a 52 week low of $72.69 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same quarter last year, the company posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on BSX. Mizuho cut their target price on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a report on Monday, February 2nd. Barclays reduced their price objective on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research note on Tuesday, February 3rd. Wells Fargo & Company cut their price target on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Finally, Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $108.36.

Insider Buying and Selling

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. 0.50% of the stock is owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.